Should Pathologists Routinely Report Prostate Tumour Volume? The Prognostic Value of Tumour Volume in Prostate Cancer

European Urology

Volumn 57, Issue 5, 2010, Pages 821-829

  Wolters, Tineke ^a   Roobol, Monique J ^a   van Leeuwen, Pim J ^a   van den Bergh, Roderick C N ^a   Hoedemaeker, Robert F ^b   van Leenders, Geert J L H ^a   Schröder, Fritz H ^a   van der Kwast, Theodorus H ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SINT FRANCISCUS GASTHUIS   (Netherlands)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Prognosis; Prostate cancer; Radical prostatectomy; Relative tumour volume; Tumour volume

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURGERY; COMPUTER ANALYSIS; CONTROLLED STUDY; DISTANT METASTASIS; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; ORGAN SIZE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; SEMINAL VESICLE;

HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGAN SIZE; PATHOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 77949492547     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.07.027     Document Type: Article

References (32)

1. Stamey T.A., McNeal J.E., Yemoto C.M., Sigal B.M., and Johnstone I.M. Biological determinants of cancer progression in men with prostate cancer. JAMA 215 (1999) 1395-1400
2. Kikuchi E., Scardino P.T., Wheeler T.M., Slawin K.M., and Ohori M. Is tumor volume an independent prognostic factor in clinically localized prostate cancer?. J Urol 172 (2004) 508-511
3. Vollmer R.T. Percentage of tumor in prostatectomy specimens. Am J Clin Pathol 131 (2009) 86-91
4. McNeal J.E., Bostwick D.G., Kindrachuk R.A., Redwine E.A., Freiha F.S., and Stamey T.A. Patterns of progression in prostate cancer. Lancet 1 (1986) 60-63
5. Epstein J.I., Carmichael M., Partin A.W., and Walsh P.C. Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of follow-up. J Urol 149 (1993) 1478-1481
6. Salomon L., Levrel O., Anastasiadis A.G., et al. Prognostic significance of tumor volume after radical prostatectomy: a multivariate analysis of pathological prognostic factors. Eur Urol 43 (2003) 39-44
7. Ramos C.G., Roehl K.A., Antenor J.A.V., Humphrey P.A., and Catalona W.J. Percent carcinoma in prostatectomy specimens is associated with risk of recurrence after radical prostatectomy in patients with pathologically organ confined prostate cancer. J Urol 172 (2004) 137-140
8. Cheng W.S., Frydenberg M., Bergstralh E.J., Lrson-Keller J.J., and Zincke H. Radical prostatectomy for pathologic stage C prostate cancer: influence of pathologic variables and adjuvant treatment on disease outcome. Urology 43 (1993) 283-291
9. Merrill M.M., Lane B.R., Reuther A.M., Zhou M., Magi-Galluzzi C., and Klein E.A. Tumor volume does not predict for biochemical recurrence after radical prostatectomy in patients with surgical Gleason score 6 or less prostate cancer. Urology 70 (2007) 294-298
10. Epstein J.I., Oesterling J.E., and Walsh P.C. Tumor volume versus percentage of specimen involved by tumor correlated with progression in stage A prostatic carcinoma. J Urol 139 (1988) 980-984
11. Partin A.W., Epstein J.I., Cho K.R., Gittelsohn A.M., and Walsh P.C. Morphometric measurement of tumor volume and percent of gland involvement as predictors of pathological stage in clinical stage B prostate cancer. J Urol 141 (1989) 341-345
12. In: Sobin L.H., and Wittekind C. (Eds). TNM classification of malignant tumours. 6th ed. (2002), Wiley-Liss, New York, NY
13. Freedland S.J., Partin A.W., Epstein J.I., and Walsh P.C. Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b. Cancer 100 (2004) 1646-1649
14. Hong S.K., Han B.K., Chung J.S., et al. Evaluation of pT2 subdivisions in the TNM staging system for prostate cancer. BJU Int 102 (2008) 1092-1096
15. Hoedemaeker R.F., Ruijter E.T.G., Ruizeveld-de Winter J.A., van der Kaa C.A., van der Kwast T.H., and BIOMED II MPC Study Group. Processing radical prostatectomy specimens. A comprehensive and standardized protocol. J Urol Pathol 9 (1998) 211-222
16. Hoedemaeker R.F., Rietbergen J.B.W., Kranse R., van der Kwast T.H., and Schröder F.H. Comparison of pathological characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer. World J Urol 15 (1997) 339-345
17. Freedland S.J., Sutter M.E., Dorey F., and Aronson W.J. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Urology 61 (2003) 365-369
18. De Koning H.J., Blom J., Merkelbach J.W., et al. Determining the cause of death in randomized screening trial(s) for prostate cancer. BJU Int 92 Suppl 2 (2003) 71-78
19. Stamey T.A., Freiha F.S., McNeal J.E., Redwine E.A., Whittemore A.S., and Schmid H.P. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 71 (1993) 933-938
20. Villers A., Puech P., Mouton D., Leroy X., Ballereau C., and Lemaitre L. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol 176 (2006) 2432-2437
21. Lemaitre L., Puech P., Poncelet E., et al. Dynamic contrast-enhanced MRI of anterior prostate cancer: morphometric assessment and correlation with radical prostatectomy findings. Eur Radiol 19 (2009) 470-480
22. Kirkham A.P.S., Emberton M., and Allen C. How good is MRI at detecting and characterizing cancer within the prostate?. Eur Urol 50 (2006) 1163-1175
23. Coakley F.V., Kurhanewicz J., Lu Y., et al. Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology 223 (2002) 91-97
24. Vis A.N., Roemeling S., Kranse R., Schröder F.H., and van der Kwast T.H. Should we replace the Gleason score with the amount of high-grade prostate cancer?. Eur Urol 51 (2007) 931-939
25. Chen M.E., Johnston D., Reyes A.O., Soto C.P., Babaian R.J., and Troncoso P. A streamlined three-dimensional volume estimation method accurately classifies prostate tumors by volume. Am J Surg Pathol 27 (2003) 1291-1301
26. Dvorak T., Chen M.-H., Renshaw A.A., Loffredo M., Richie J.P., and d'Amico A.V. Maximal tumor diameter and the risk of PSA failure in en with specimen-confined prostate cancer. J Urol 66 (2005) 1024-1028
27. Eichelberger L.E., Koch M.O., Eble J.N., Ulbright T.M., Juliar B.E., and Cheng L. Maximum tumor diameter is an independent predictor of prostate specific antigen recurrence in prostate cancer. Mod Pathol 18 (2005) 886-890
28. Marks R.A., Lin H., Koch M.O., and Cheng. Positive-block ratio in radical prostatectomy specimens is an independent predictor of prostate-specific antigen recurrence. Am J Surg Pathol 31 (2007) 877-881
29. Billis A., Magna L.A., and Ferreira U. Correlation between tumor extent in radical prostatectomies and preoperative PSA, histological grade, surgical margins and extraprostatic extension; application of a new practical method for tumor extent evaluation. Int Braz J Urol 29 (2003) 113-120
30. Carvalhal G.F., Humphrey P.A., Thorson P., Yan Y., Ramos C.G., and Catalona W.J. Visual estimate of the percentage of carcinoma is an independent predictor of prostate carcinoma recurrence after radical prostatectomy. Cancer 89 (2000) 1308-1314
31. van Oort I.M., Witjes J.A., Kok D.E., Kiemeney L.A., and Hulsbergen-vandeKaa C.A. Maximum tumor diameter is not an independent prognostic factor in high-risk localized prostate cancer. World J Urol 26 (2008) 237-241
32. Scattoni V., Montironi R., Mazzucchelli R., et al. Pathological changes if high-grade prostatic intraepithelial neoplasia and prostate cancer after monotherapy with bicalutamide 150 mg. BJU Int 98 (2006) 54-58